Last reviewed · How we verify
SR419
At a glance
| Generic name | SR419 |
|---|---|
| Sponsor | Shanghai SIMR Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 (PHASE1, PHASE2)
- The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers (PHASE1)
- The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers (PHASE1)
- To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN) (PHASE2)
- A Study to Assess the Pharmacokinetics and Food Effect of SR419 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR419 CI brief — competitive landscape report
- SR419 updates RSS · CI watch RSS
- Shanghai SIMR Biotechnology Co., Ltd. portfolio CI